According to Bloomberg, all eight research firms currently covering RAPT Therapeutics, Inc. (NASDAQ: RAPT) have rated the stock as a “buy,” making it the consensus recommendation for investors to purchase the company’s shares. Furthermore, seven equity research professionals have argued in their publications that investors should buy the stock in question. In addition, most brokerage firms that have covered the stock in the preceding year have projected to reach an average price of $43.50 within the next year, which they have set as their target price.
Recent reports on RAPT have been compiled by a few brokerage firms, now available on their respective websites. The Goldman Sachs Group published its first research report covering RAPT Therapeutics on December 1, a Thursday. This report marked the beginning of the firm’s coverage of the company. They suggested buying the stock for $27.00, and they decided that the price at which to sell it should also be $27.00. The research study relating to RAPT Therapeutics was initially made available to the public by Capital One Financial on September 21, the day after it was initially published. They provided the company with an “overweight” rating and set the price objective for the stock at $48,00. In a research note published on December 8, Piper Sandler stated their intention to lower their target price for RAPT Therapeutics from $34.00 to $33.00. Finally, HC Wainwright assigned the company the rating of “buy” in a research analysis published on Monday, November 14, and lowered its target price on RAPT Therapeutics from $53.00 to $50.00. The report was issued on Monday, November 14. The report contains this information as part of its entirety.
NASDAQ: RAPT was first available for trading on Friday with an opening price of $17.89. The lowest price RAPT Therapeutics has reached in the past year is $9.85, while the highest price the company’s stock has reached in the past year is $40.74. The price-to-earnings ratio of the business is -7.02, and its beta value comes in at 0.35. The company currently has a market capitalization of $535.11 million price of $17.89. The lowest price RAPT Therapeutics has reached in the past year is $9.85, while the highest price the company’s stock has reached in the past year is $40.74. The price-to-earnings ratio of the business is -7.02, and its beta value comes in at 0.35. The company currently has a market capitalization of $535.11 million. The stock’s moving average over the past 50 days is $19.97, and its moving average over the past 200 days is $21.15.
According to additional news concerning the company, on November 2, an insider named William Ho sold 5,000 shares. This transaction was reported in other news regarding the company. The price of each share, which was ultimately sold for a total of $111,600.00, was broken down to an average of $22.32 per share. This price was determined by dividing the total sale price. Following the successful transaction completion, the company insider now directly owns 47,650 shares of the company’s stock. The total value of these shares is approximately $1,063,548. You will be taken to a filing with the Securities and Exchange Commission if you click on the link provided, where you can obtain additional information regarding the sale. Insiders of the company have sold 12,000 shares over the past three months, generating a total of 243,990 dollars in profit. The management and employees of the company collectively hold 5% of the total number of shares.
In recent weeks, RAPT has undergone some changes due to the efforts of various institutional investors, including hedge funds and other types. The Swiss National Bank increased the proportion of RAPT Therapeutics stock owned by 7.6% during the first three months of 2018. There are currently 45,400 shares in the company that is directly held by the Swiss National Bank, which has a value of $998,000. This is a direct consequence of the financial institution’s purchase of 3,200 additional shares over the most recent three months. GSA Capital Partners LLP successfully increased its holdings in RAPT Therapeutics by 115.3% during the first three months of 2018. After making additional purchases of 10,131 shares throughout the period, GSA Capital Partners LLP is now the owner of 18,915 shares of the company’s stock. These purchases were made during the period. Based on their current market price, the total value of these shares comes to $416,000 right now. JPMorgan Chase & Co. increased the proportion of RAPT Therapeutics stock owned by an additional 23.7% over the first three months of 2018. After making an additional purchase of 2,599 shares throughout the relevant period, JPMorgan Chase & Co. currently possesses 13,575 shares in the company, which have an estimated market value of $299,000. These shares were acquired during the period in question. During the first quarter, MetLife Investment Management LLC increased the total number of shares of RAPT Therapeutics owned by a percentage equal to 58.5%. After purchasing an additional 4,070 shares during the period, MetLife Investment Management LLC now has 11,028 shares. Based on today’s trade, the value of these shares is $243,000, bringing the total number of shares that the company owns to 11,028. And finally, during the first three months of this year, Rhumbline Advisers increased the proportion of RAPT Therapeutics stock owned by an additional 18.3%. Following the acquisition of a further 3,405 shares during the period in question, Rhumbline Advisers now holds 21,961 shares of the company’s stock, which have a market value of $483,000. Institutional investors and hedge funds own 98.42% of the company’s stock. Rhumbline Advisers is an investment advisory firm that is registered.
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company with the mission to discover, develop, and commercialize oral small-molecule medicines for patients with unmet medical needs who are afflicted with inflammatory and malignant conditions. RAPT Therapeutics was founded to provide patients with unmet medical needs afflicted with conditions like cancer with access to medicines that can treat their symptoms. The company’s primary candidate for an anti-inflammatory medicine is RPT193, which is an antagonist for the C-C motif chemokine receptor 4 (CCR4). It accomplishes this by inhibiting the movement of type 2 T helper cells into the inflammatory areas of the body.
Read More: Brokerages Consensus Recommendation: “Buy” for RAPT Therapeutics, Inc. (NASDAQ:RAPT).